BioNTech SE (BNTX) Closes the Acquisition of CureVac N.V.

BioNTech SE (NASDAQ:BNTX) is one of the Stocks That Will Go To The Moon in 2026. On December 18, BioNTech SE (NASDAQ:BNTX) announced the closing of its acquisition of CureVac N.V. (NASDAQ:CVAC), which is another mRNA-focused biotech firm from Mainz, Germany.

Management noted that the deal had closed after the expiration of the subsequent offering period in exchange for CureVac’s shares. As a result, the company now holds a majority stake in CureVac. This enables the company to integrate CureVac’s pipeline for oncology and infectious diseases.

In another update, on December 11, H.C. Wainwright reiterated a Buy rating on BioNTech SE (NASDAQ:BNTX) with a $140 price target.

The bullish sentiment is based on the interim data from a Phase 2 trial testing Pumitamig (BNT327/BMS-986545), which is a bispecific antibody that targets both PD-L1 and VEGF-A. The treatment is being tested for patients with triple-negative breast cancer (TNBC). The results showed strong anti-tumor activity and tolerable safety. Management noted that the results support advancing to a Phase 3 trial called ROSETTA-BREAST-01.

H.C. Wainwright noted that the trial showed an impressive 72% overall response rate along with 62% confirmed ORR in first-line and second-line TNBC patients. The firm added that these impressive results derisk the ongoing phase 3 trials, suggesting the strong potential of Pumitamig plus chemotherapy becoming a treatment for first-line TNBC patients with PD-L1 expression.

BioNTech SE (NASDAQ:BNTX) is a German biotechnology company that develops and commercializes novel immunotherapies and vaccines for cancer and infectious diseases. It is widely recognized for creating the first approved mRNA-based drug, the Pfizer-BioNTech COVID-19 vaccine, sold under the brand name Comirnaty.

While we acknowledge the potential of BNTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.